Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Cohen JA, Imrey PB, Calabresi PA, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Mandell BF, Scott TF, Zhang H, Apperson-Hansen C, Beck GJ, Houghtaling PL, Karafa MT, Stadtler M; ACT Investigators. Cohen JA, et al. Neurology. 2009 Feb 10;72(6):535-41. doi: 10.1212/01.wnl.0000341934.12142.74. Neurology. 2009. PMID: 19204263 Clinical Trial.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Cohen JA, Calabresi PA, Chakraborty S, Edwards KR, Eickenhorst T, Felton WL 3rd, Fisher E, Fox RJ, Goodman AD, Hara-Cleaver C, Hutton GJ, Imrey PB, Ivancic DM, Mandell BF, Perryman JE, Scott TF, Skaramagas TT, Zhang H; ACT Investigators. Cohen JA, et al. Mult Scler. 2008 Apr;14(3):370-82. doi: 10.1177/1352458507083189. Epub 2008 Jan 21. Mult Scler. 2008. PMID: 18208877 Clinical Trial.
Blood-based targeted metabolipidomics reveals altered omega fatty acid-derived lipid mediators in relapsing-remitting multiple sclerosis patients.
Zahoor I, Waters J, Ata N, Datta I, Pedersen TL, Cerghet M, Poisson L, Markovic-Plese S, Rattan R, Taha AY, Newman JW, Giri S. Zahoor I, et al. Among authors: markovic plese s. bioRxiv [Preprint]. 2024 Jan 6:2024.01.04.574253. doi: 10.1101/2024.01.04.574253. bioRxiv. 2024. PMID: 38260401 Free PMC article. Preprint.
IL-11 induces NLRP3 inflammasome activation in monocytes and inflammatory cell migration to the central nervous system.
Seyedsadr M, Wang Y, Elzoheiry M, Shree Gopal S, Jang S, Duran G, Chervoneva I, Kasimoglou E, Wrobel JA, Hwang D, Garifallou J, Zhang X, Khan TH, Lorenz U, Su M, Ting JP, Broux B, Rostami A, Miskin D, Markovic-Plese S. Seyedsadr M, et al. Among authors: markovic plese s. Proc Natl Acad Sci U S A. 2023 Jun 27;120(26):e2221007120. doi: 10.1073/pnas.2221007120. Epub 2023 Jun 20. Proc Natl Acad Sci U S A. 2023. PMID: 37339207 Free PMC article.
Corrigendum to "Oligoclonal myelin-reactive T-cell infiltrates derived from neuromyelitis optica spectrum disorder (NMOSD) lesions are enriched in Th17 cells" [Clinical Immunology 130 (2009) 133-144].
Montes M, Zhang X, Berthelot L, Laplaud DA, Brouard S, Jin J, Rogan S, Armao D, Jewells V, Soulillou JP, Markovic-Plese S. Montes M, et al. Among authors: markovic plese s. Clin Immunol. 2022 Apr;237:108967. doi: 10.1016/j.clim.2022.108967. Epub 2022 Mar 17. Clin Immunol. 2022. PMID: 35307286 Free PMC article. No abstract available.
70 results